Cereno Scientific announces first subjects dosed in clinical study with drug candidate CS1
Cereno Scientific (Aktietorget: “CRNO B”), a pharmaceutical company developing a new preventive medicine to treat thrombosis-related disease, today announced dose administration for the first subjects in its recently approved clinical study with drug candidate, CS1.The study, which is being conducted together with Cereno Scientific’s clinical research partner, CTC, is assessing the safety and tolerability, as well as the pharmacokinetics, of CS1 in adults with borderline hypertension and obesity. It is also investigating the efficacy of CS1 on biomarkers related to risk for thrombosis-